贝伐单抗联合顺铂胸腔内灌注治疗非小细胞肺癌恶性胸腔积液的疗效和安全性  

Effect and Safety of Bevacizumab Combined with Cisplatin Intrapleural Infusion in the Treatment of Malignant Pleural Effusion of Non-Small Cell Lung Cancer

作　　者：石永康 SHI Yongkang(People's Hospital of Jintan District,Changzhou,Jiangsu 213200,China)

机构地区：[1]常州市金坛区人民医院,江苏常州213200

出　　处：《大医生》2019年第13期114-115,共2页Doctor

摘　　要：目的探讨贝伐单抗联合顺铂胸腔内灌注治疗非小细胞肺癌恶性胸腔积液的疗效和安全性。方法选取2014年1月至2019年1月常州市金坛区人民医院收诊的50例非小细胞肺癌恶性胸腔积液患者,随机分为观察组25例(顺铂联合贝伐单抗)与对照组25例(顺铂),比较两组治疗有效率、不良反应发生率。结果治疗后观察组治疗有效率高于对照组(96.00%vs.72.00%),不良反应发生率低于对照组(4.00%vs.24.00%),差异有统计学意义(P<0.05)。结论贝伐单抗联合顺铂胸腔内灌注可有效提高非小细胞肺癌恶性胸腔积液患者预后质量及安全性,值得推广使用。Objective To investigate the effect and safety of bevacizumab combined with cisplatin intrapleural infusion in the treatment of malignant pleural effusion of non-small cell lung cancer(NSCLC).Methods Fifty NSCLC patients with malignant pleural effusion were enrolled in our hospital from January 2014 to January 2019 and randomly divided into the observation group(25 cases,cisplatin combined with bevacizumab)and the control group(25 cases,cisplatin).The effective rate and adverse reaction rate were compared between the two groups.Results After treatment,the total effective rate of the observation group was higher than that in the control group(96.00%vs.72.00%,P<0.05),and the incidence of adverse reactions was lower than that in the the control group(4.00%vs.24.00%,P<0.05).Conclusion Bevacizumab combined with cisplatin intrapleural infusion can effectively improve the prognosis quality and effect of NSCLC patients with malignant pleural effusion.It is worthy of popularization.

关 键 词：安全性 非小细胞肺癌 恶性胸腔积液 顺铂 贝伐单抗 

分 类 号：R73[医药卫生—肿瘤]